TABLE 1

COPD patient demographics

Treatment group
Placebo#50 µg RV568#100 µg RV568#
Age years66±562±560±5
Sex
 Male744
 Female466
Race
 White10109
 Other001
Weight kg78.9±13.670.9±14.070.6±13.1
Height cm173±12164±12164±10
BMI kg·m−226.3±2.826.7±5.526.4±4.3
Post-bronchodilator FEV1 % predicted67±1065±962±11
Post-bronchodilator FEV1/FVC ratio %52.2±10.249.2±12.548.1±11.6
Smoking status
 Current554
 Former556
COPD therapy
 Single (SABA, LABA or LAMA)244
 Dual (ICS/LABA or LABA/LAMA)222
 Triple (ICS/LABA/LAMA)644

Data are presented as mean±sd or n. COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting beta agonists; LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroids. #: n=10.